

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.

Learn more: [PMC Disclaimer](#) | [PMC Copyright Notice](#)



JMIR Cancer

Patient-Centered Innovations, Education and Technology for Cancer

[cancer.jmir.org](https://cancer.jmir.org)

[JMIR Cancer](#). 2022 Jul-Sep; 8(3): e34851.

PMCID: PMC9412760

Published online 2022 Aug 11. doi: [10.2196/34851](https://doi.org/10.2196/34851)

PMID: [35969424](https://pubmed.ncbi.nlm.nih.gov/35969424/)

## Impact of a Personal Health Record Intervention Upon Surveillance Among Colorectal Cancer Survivors: Feasibility Study



Monitoring Editor: Amaryllis Mavragani

Reviewed by Catherine Smith, Songphan Choemprayong, and Mohammad Mansourzadeh

[Eric Vachon](#), PhD, RN,<sup>#1,2</sup> [Bruce W Robb](#), MD,<sup>#3</sup> and [David A Haggstrom](#), MD, MAS<sup>#2,4</sup>

<sup>1</sup> School of Nursing, Indiana University, Indianapolis, IN, United States

<sup>2</sup> Center for Health Services Research, Regenstrief Institute, Indianapolis, IN, United States

<sup>3</sup> Department of Surgery, School of Medicine, Indiana University, Indianapolis, IN, United States

<sup>4</sup> Division of General Internal Medicine and Geriatrics, School of Medicine, Indiana University, Indianapolis, IN, United States

Eric Vachon, School of Nursing, Indiana University, NU W427, 600 Barnhill Dr., Indianapolis, IN, 46202, United States, Phone: 1 317 278 6064, Email: [evachon@iu.edu](mailto:evachon@iu.edu).

[Copyright](#) ©Eric Vachon, Bruce W Robb, David A Haggstrom. Originally published in JMIR Cancer (<https://cancer.jmir.org>), 11.08.2022.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cancer, is properly cited. The complete bibliographic information, a link to the original publication on <https://cancer.jmir.org/>, as well as this copyright and license information must be included.

### Abstract

 Feedback

### Background

There are currently an estimated 1.5 million individuals living in the United States with colorectal cancer (CRC), and although the 5-year survival rate has increased, survivors are at risk for recurrence, particularly within the first 2-3 years after treatment. National guidelines recommend continued surveillance after resection to identify recurrence early on. Adherence among survivors ranges from 23% to 94%. Novel interventions are needed to increase CRC survivors' knowledge and confidence in managing their cancer and thus to increase adherence to follow-up surveillance.

## Objective

The objective of this study is to develop and test the feasibility and efficacy of a stand-alone, web-based personal health record (PHR) to increase surveillance adherence among CRC survivors, with patient beliefs about surveillance as secondary outcomes.

## Methods

A pre- and postintervention feasibility trial was conducted testing the efficacy of the colorectal cancer survivor (CRCS)-PHR, which had been previously developed using an iterative, user-centered design approach.

## Results

The average age of the sample was 58 (SD 9.9) years, with 57% (16/28) male and the majority married (20/28, 71%) and employed full-time (15/28, 54%). We observed a significant increase in adherence to colonoscopy (before: 11/21, 52% vs after: 18/21, 86%;  $P=.005$ ) and CEA (14/21, 67% vs 20/21, 95%;  $P=.01$ ), as well as a slight increase in CT scans (14/21, 67% vs 18/21, 86%;  $P=.10$ ). The only significant impact on secondary outcome (patient beliefs) was benefits of CEA test ( $P=.04$ ), as most of the beliefs were high at baseline.

## Conclusions

This feasibility study lays the groundwork for continued development of the CRCS-PHR to increase CRC surveillance. Patient-centered technologies, such as the CRCS-PHR, represent an important potential approach to improving the receipt of guideline-concordant care and follow-up surveillance, and not just for CRC survivors. Researchers should continue to develop patient-centered health technologies with clinician implementation in mind to increase patient self-efficacy and surveillance adherence.

**Keywords:** personal health record, colorectal cancer survivors, surveillance, health record, survivor, cancer, oncology, colorectal, United States, North America, feasibility, web-based, patient belief, patient attitude, survival

## Introduction

There are an estimated 1.5 million individuals living in the United States with colorectal cancer (CRC), and an estimated 150,000 new cases will be diagnosed during 2021 [1]. While the 5-year survival rate has increased to 65%, survivors are still at risk for cancer recurrence with >40% developing recurrent disease within 5 years, and 80% of recurrences happening within the first 2-3 years after treatment. National professional guidelines recommend follow-up or surveillance tests such as colonoscopy, carcinoembryonic antigen (CEA), and computed tomography (CT) scans at specific intervals after treatment [2-4]. Survivor adherence to recommended surveillance is often poor and ranges between 23% and 94% [5-11]. Novel interventions to increase guideline-concordant surveillance, thus, are needed to improve the quality of care and outcomes among cancer survivors. In the United States, national incentives for offering access to electronic personal health records (PHRs) have promoted patient engagement through information technology [12-17]. Patient-centered health-information technologies are potentially valuable tools for survivorship care planning to increase knowledge about surveillance tests, self-efficacy, and ultimately adherence to guideline-concordant surveillance [16-21].

Web-based technologies have the capacity to reach large numbers of patients efficiently. PHR use has expanded over time [22-25], with functions developed for individuals with various chronic diseases and across the lifespan [17,26-29]. These functions may vary widely depending on the context of PHR implementation. While there exists a variety of PHRs, there are three primary categories of PHRs, which are as follows: (1) stand-alone PHRs, which do not directly connect with any other electronic systems or networks; (2) tethered PHRs, often referred to as patient portals or web-based portals, which connect with the web-based network and electronic medical record of a specific institution; and (3) integrated PHRs, which are able to connect to multiple data networks and institutions [17,19,21]. While these different types of PHR categories describe general trends, there is a fair amount of overlap in terms of functionalities. PHRs have the potential to engage patients with cancer and cancer survivors to play a more active role in their surveillance care and to increase self-efficacy and knowledge about surveillance [16-21]. Providing patients access to their own health information, management strategies, web-based resources, and communication tools with providers can increase self-management and the quality of patient-provider communication, which lead to better patient outcomes [16,17,19,21]. However, PHRs tailored to the needs of cancer survivors have not been widely developed or tested for certain cancer site populations, including CRC. Among patients with cancer, PHRs have been mainly developed that target patients with breast and lung cancer as well as breast and lung cancer survivors [30,31]. Technology-based interventions have been limited in targeting CRC survivors who are at substantial risk for recurrent disease within the first couple of years after treatment and may benefit from the use of technology-based interventions. Given these issues, there is a considerable need for the development of technology-based interventions, such as PHRs, targeted toward patients with CRC, particularly to increase adherence to the recommended surveillance [16,17,19,21].

The purpose of this pilot trial was to test the feasibility and evaluate the effectiveness of a stand-alone PHR in increasing surveillance testing (colonoscopy, CEA, and CT scan) among CRC survivors. Moreover, the study assessed the impact of the PHR upon the secondary outcomes of patient self-efficacy, knowledge regarding surveillance, and CRC patients' perceptions of benefits and barriers to surveillance testing. The Colorectal Cancer Survivor (CRCS)-PHR was designed using

open-source software to increase guideline-concordant CRC surveillance by delivering patients reminders and tracking tools regarding surveillance tests for which they were eligible. This work has the potential to benefit both researchers focused on developing technology-based interventions for patients, particularly cancer survivors, as well as clinicians who are working toward increasing adherence to guidelines.

## Methods

---

### Colorectal Cancer Survivors' Personal Health Record

We developed the CRCS-PHR as a stand-alone, web-based tool for patient convenience, portability, and dissemination potential. An iterative, user-centered design approach was followed during development, including the creation of clinical content, program design, and web design usability testing. The design process began with the creation of content and technical parameters, culminating in a web-based interactive prototype. Product development included the application of established usability methods [32]. Stakeholders (consisting of patients, caregivers, and health care providers) were asked to participate in scenario-based evaluations with direct observation and debriefing interviews to gather data on user performance and preferences as described elsewhere [33]. Changes were not made in the web-based design until data from at least 4-6 stakeholders had been collected; consistent with previous work by Nielsen et al [34], a total of 17 stakeholders participated in data collection.

The CRCS-PHR includes the following clinical information: CRC surveillance guidelines, treatment received (surgery; adjuvant therapy; and lab, radiology, and procedure results), and potential future toxicities of the treatment received. The CRCS-PHR also had the ability to collect personal observations from the CRC survivor in an electronic journal or blog, relationships with providers and family members or friends, and communities with other CRC survivors.

Surveillance guidelines included information about guideline-concordant surveillance care, including bowel surveillance (colonoscopy), CEA tests, and CT scans [2], with reminders for individual surveillance tests based on individuals' needs. Recommendations for surveillance care were adapted from the guidelines of professional organizations [2]. Information about CRC surveillance guidelines were automatically tailored to the CRC survivor's disease stage (eg, CEA testing was not to be recommended for patients with stage I CRC). In the CRC-PHR, 2 tables related to surveillance care were delivered to the patient (Figure 1). First, a table was generated, which indicated what surveillance tests were appropriate for the patient and by what dates the tests should be performed. This informational table was designed to increase patient knowledge about surveillance and its benefits, as well as to prompt CRC survivors to seek the receipt of surveillance tests [35]. Second, a table was created wherein patients could self-enter information about the surveillance test received (date completed, type of test, and a brief description of results). This interactive table was designed both to enable the tracking of completed tests and to promote patient self-efficacy; interactivity is widely believed to enhance user involvement, commitment, and learning [36].

Welcome to the 'My Plan of Care' Tab, where you can:

- Review follow-up care (or surveillance tests) that you and your doctor may consider given your type of cancer
- The Calendar on the left reflects a potential follow-up schedule given the date of your cancer diagnosis.
- The Follow-up Care Received on the right provides a place for you to enter and track surveillance tests.

Potential Follow-up Care Calendar		Follow-up Care Received (as recorded by you, the patient)				
Target Dates	Recommended Care	Date Completed	Care Received	Doctor Name	Comments	Action
01/07/2013	Colonoscopy (COMPLETED 12/14/2012)	12/14/2012	Colonoscopy	Dr. Febbit	no polyps - OK	Save Delete
07/20/2018	Colonoscopy (COMPLETED 09/03/2018)	09/03/2018	Colonoscopy	Dr. Tarver	normal	Save Delete
07/20/2019	History and Physical					
07/20/2020	Colonoscopy					
07/20/2020	History and Physical					

(NOTE: This calendar is based on clinical guidelines for testing for cancer recurrence. As each year goes by, your risk for recurrence goes down. At the end of this period of time, no further tests for recurrence are typically recommended.)

Figure 1

Screenshot of personal health record, "My Follow-up Care" Dashboard. CEA: carcinoembryonic antigen; CT: computed tomography.

A 30-minute training session was developed to introduce patients to the content and functionality of the CRCS-PHR and was conducted in person by the research assistant at the time of recruitment. In addition, virtual training tools were embedded in the CRCS-PHR, including a 5-minute narrated training video and a detailed help section describing the purpose of all links, data-entry forms, and features of the tool.

## Study Design

A pre- and posttest intervention trial was conducted to test the feasibility and to determine the ability of the targeted PHR intervention to increase patient knowledge, self-efficacy, beliefs, and receipt of surveillance tests among CRC survivors. Participants were recruited between March and October 2012, with the postintervention follow-up survey occurring 6 months after the baseline survey.

## Sample and Recruitment

Patients with CRC were eligible to participate if they had received curative-intent therapy and had been diagnosed with American Joint Committee on Cancer Stage I-III adenocarcinoma at least 9 months (but no more than 24 months) earlier. Participants were excluded from the study if they had metastatic disease. We approached CRC survivors for recruitment at an academic medical center and the Veterans Affairs (VA) hospital in Indianapolis. At the academic medical center, patients were seen in surgery clinics led by CRC surgeons.

## Data Collection and Measures

Data were collected via patient self-report. Self-reported data are a valid, widely accepted source about clinical service use due to cost and time efficiency, particularly for early-phase studies such as this feasibility study, as well as large-scale epidemiologic studies [37-40]. Presurvey measure-

ments were collected by a research assistant at baseline immediately after the patient was provided with access to the CRCS-PHR. Postsurvey measurement was then collected 6 months after initial enrollment over the telephone, with a written survey being mailed beforehand to patients in order to facilitate answering the questions. In addition to the measures discussed below, participants were asked how they used the PHR and what features they found to be most and least useful after the intervention.

## Measurements

**Patient and Clinical Characteristics** Patient sociodemographic characteristics were collected during the baseline survey. Clinical characteristics regarding anatomic cancer site (colon or rectum), stage, and treatment (surgery, radiation treatment, and chemotherapy) were collected via medical record audit at the time of enrollment.

**Patient-Centered Behavior Outcomes** Patient-centered behavior outcomes were all collected during the pre- and postintervention surveys. These outcomes included self-efficacy, perceived benefits of surveillance testing, barriers to adherence of surveillance testing, and knowledge of CRC surveillance testing. For self-efficacy, the General Self-Efficacy (GSE) scale was used, which consists of 10 items using a 4-point Likert scale ([Multimedia Appendix 1](#)) [41]. The GSE scale measures general self-efficacy and has been translated into more than 30 languages. The GSE scale had a Cronbach alpha of .86 in the current sample. For perceived benefits of CRC surveillance testing, a 5-item Likert scale was used, with the last 3 items each including a question dedicated to each of the 3 surveillance tests (colonoscopy, CEA test, and CT scan). For barriers to adherence to surveillance testing, a 3-item Likert scale was used. The items regarding perceived benefits and barriers were drawn from domains originally identified as being related to CRC screening by Rawl et al [42,43] among first-degree relatives of patients with CRC.

**Surveillance Receipt** Adherence to surveillance testing was captured via patient report during both the pre- and postintervention surveys. Patients were asked yes or no if they had undergone each of the following tests since having CRC surgery: colonoscopy, CEA test, and CT scan.

**Patient Knowledge** Patient knowledge regarding follow-up surveillance tests and visits was assessed by asking participants how often they believe each surveillance test (colonoscopy, CEA test, CT scan, and physical examination) should be performed. Participants were given various time frame categories to choose from. The guideline-concordant test frequency is as follows: physical exam, 3-6 months; CEA test, 3-4 months; colonoscopy, 2-3 years; and CT scan, annually [2]. For each participant, the number of items answered correctly was summed to generate the knowledge score (0-4). Patient knowledge was assessed at both baseline and after the intervention.

**Statistical Analysis** Frequencies and measures of central tendency were calculated for patient sociodemographic variables. Descriptive statistics were calculated for sociodemographics, patients' beliefs about surveillance tests categories (knowledge, self-efficacy, barriers, and benefits), and receipt of surveillance tests (colonoscopy, CEA test, and CT scan). Paired *t* test (2-tailed) was used to examine the differences in patient-centered behavior outcomes pre- and postintervention delivery. To examine the differences in surveillance receipt before and after the intervention, McNemar test

was used. Patients who did not complete the follow-up survey were excluded from the primary analysis. The excluded participants were compared to those who completed both surveys in terms of sociodemographic and clinical characteristics; no differences were found. Data were analyzed using STATA 16.1 (StataCorp).

## Ethical Considerations

Approval for this study was obtained by the Indiana University Institutional Review Board (1201007805), as well as the Indianapolis VA Research & Development committee. The procedures used in this study adhere to the guidelines of the World Medical Association Declaration of Helsinki. Prior to enrollment in the study, the purpose of the study and each participant's role were explained. Written consent was obtained from everyone who participated.

## Results

---

### Patient Characteristics

A total of 28 patients with CRC completed the baseline survey, with 22 patients completing the follow-up survey at 6 months after the intervention. The majority of the sample was recruited at Indiana University Health (25/28, 89%), with 3 patients being recruited through the Indianapolis VA Medical Center. [Table 1](#) describes the patient sociodemographics. The average age of the sample was 58 (SD 9.9) years. Two-thirds (18/28, 64%) of the patients had rectal cancer vs colon cancer (9/28, 33%). The majority of the patients were male (16/28, 57%), married (20/28, 71%), and were employed full-time (15/28, 54%); they also had an annual household income of >US \$60,000 (16/28, 57%). Slightly less than half of patients (13/28, 46%) had a college education or greater.

**Table 1**

Demographic characteristics (N=28).

Characteristics	
Age (years), mean (SD)	
<b>Sex, n (%)</b>	
	Male
	Female
<b>Cancer type, n (%)</b>	
	Colon
	Rectal
	Unknown
<b>Education, n (%)</b>	
	High school
	Some college or trade school
	Associate or bachelor's degree
	Some or complete graduate school
<b>Current marital status, n (%)</b>	
	Married (or long-term commitment)
	Not Married
<b>Employment status, n (%)</b>	
	Full-time
	Part-time
	Unemployed
	Retired
	Unable to work
<b>Income (US\$), n (%)</b>	
	<30,000
	30,001-59,999
	>60,000

**Patient-Centered Behavior Outcomes**

Descriptive statistics and paired *t* test results for the 4 categories of behavior outcomes, including self-efficacy, perceived benefit, perceived barriers, and patient knowledge, both before and after the intervention are reported in [Table 2](#), while [Tables 3-5](#) provide a more in-depth view of how patients answered the baseline questions for the 3 categories of knowledge, barriers, and benefits. For knowledge, patients were asked about the correct intervals of recommended follow-up times for various surveillance tests (physical exam, CEA test, colonoscopy, and CT scan). Out of the 4 knowledge questions, patients answered on average just under 2 of the 4 correctly, with no change in knowledge between the two surveys ( $P=.69$ ). Self-efficacy (range 10-40) saw little change between pre- (32.2) and postintervention surveys (31.8;  $P=.66$ ). Patients rated barriers (range 3-15) at both intervals fairly low, with 4.7 before the intervention and 4.9 at after the intervention ( $P=.81$ ). Benefits (range 5-25) is the only beliefs category in which we saw a significant change, and this was only benefits for CEA test, as benefits for all tests were rated fairly high. For colonoscopy, patients rated benefits before the intervention at 22.6, with no change after the intervention at 22.8 ( $P=.75$ ). CEA test was rated as 20.9 before the intervention, with 22.0 after the intervention ( $P=.04$ ). CT scan saw little change with preintervention rating at 21.6 and postintervention rating at 22.1 ( $P=.45$ ).

**Table 2**

Patients' beliefs about surveillance tests (n=22).

Patients' beliefs	Before intervention, mean (SD)	
Knowledge (range: 0-4)	1.7 (1.1)	
Self-efficacy (range: 10-40)	32.2 (3.6)	
Barriers (range: 3-15)	4.7 (2.2)	
<b>Benefits (range: 5-25)</b>		
Colonoscopy	22.6 (2.6)	22.8 (2.6)
CEA <sup>a</sup> test	20.9 (3.3)	22.0 (2.6)
CT <sup>b</sup> scan	21.6 (2.7)	22.1 (2.6)

<sup>a</sup>CEA: carcinoembryonic antigen.

<sup>b</sup>CT: computed tomography.

<sup>c</sup>Italicized *P* values indicate significant value at the .05 level.

Table 3

Response frequency for benefits and barriers of surveillance at baseline.

Questions and responses	Strongly c
<b>Benefits</b>	
Finding the recurrence of CRC <sup>a</sup> early will save your life.	0 (0)
The treatment for the recurrence of CRC may not be as bad if the cancer is found early.	0 (0)
<b>The following tests will help find the recurrence of CRC early:</b>	
Colonoscopy	0 (0)
CEA <sup>b</sup> test	0 (0)
CT <sup>c</sup> scan	0 (0)
<b>The following tests will decrease your chances of dying from the recurrence of CRC:</b>	
Colonoscopy	1 (4)
CEA test	1 (4)
CT scan	1 (4)
<b>The following tests will help you not worry as much about the recurrence of CRC:</b>	
Colonoscopy	2 (7)
CEA test	2 (7)
CT scan	2 (7)
<b>Barriers</b>	
You feel anxious about having follow-up tests because you don't really understand what will be done.	16 (57)
The cost would keep you from having follow-up tests.	12 (43)
Transportation problems would keep you from having follow-up tests.	15 (54)

<sup>a</sup>CRC: colorectal cancer.<sup>b</sup>CEA: carcinoembryonic antigen.<sup>c</sup>CT: computed tomography.

Table 5

Response frequency for knowledge about surveillance at baseline (continued)<sup>a</sup>.

Questions and responses	Yearly	2-3 Years	4-
<b>Knowledge</b>			
<b>How often do you believe the following cancer surveillance tests should be performed for</b>			
Colonoscopy	20 (71)	5 (18)	2 (7)
CT <sup>b</sup> scan	16 (57)	3 (11)	2 (7)

<sup>a</sup>Italicized responses are the correct answers to the frequency for each surveillance test.<sup>b</sup>CT: computed tomography.

Table 4

Response frequency for knowledge about surveillance at baseline<sup>a</sup>.

Questions and responses	3-4 Months	6 Months
<b>Knowledge</b>		
<b>How often do you believe the following cancer surveillance tests should be performed for a</b>		
Physical examination	14 (50)	7 (25)
CEA <sup>b</sup> test	14 (50)	7 (25)

<sup>a</sup>Italicized responses are the correct answers to the frequency for each surveillance test.<sup>b</sup>CEA: carcinoembryonic antigen.

## Receipt of Surveillance Testing

[Table 6](#) reports the prevalence and comparison (paired *t* test) for each of the 3 primary surveillance tests at each time point. Since having surgery, only 52% had a colonoscopy since their CRC surgery, while that number increased to 86% (18/21) after the intervention ( $P=.005$ ). Similarly, 67% (14/21) had a CEA test from the time of their surgery prior to the preintervention survey, while the proportion increased to 95% (20/21) after the intervention ( $P=.01$ ). CT scan was the only surveillance test in which we did not see a significant uptick, with 67% (14/21) reporting having had a CT scan at the beginning of the study and 86% (18/21) having had one after the intervention ( $P=.10$ ).

Table 6

Receipt of surveillance tests (n=21).

Tests	Preintervention, n (%)	Postintervention
Colonoscopy	11 (52)	18 (86)
CEA <sup>b</sup> test	14 (67)	20 (95)
CT <sup>c</sup> scan	14 (67)	18 (86)

<sup>a</sup>Italicized *P* values indicate significant value at the .05 level.

<sup>b</sup>CEA: carcinoembryonic antigen.

<sup>c</sup>CT: computed tomography.

## Discussion

### Overview

The purpose of our study was to test the feasibility of a stand-alone PHR for CRC survivors' post resection and examine its impact upon receipt of recommended surveillance testing and behavior outcomes. CRC survivors are at an increased risk of recurrence, especially within the first 2-3 years after treatment. Interventions targeted toward increasing surveillance rates for CRC survivors would help to detect signs of recurrence early in its progression, and thus potentially decrease morbidity and mortality.

### Principal Findings

For our primary outcome, we found an overall significant impact on receipt of CRC surveillance tests. From baseline to the 6-month postintervention follow-up, we saw a significant impact for both colonoscopy ( $P=.005$ ) and CEA testing ( $P=.01$ ). There was no significant increase in CT scans between before and after the intervention, although we did observe an increase from 67% (14/21) at baseline to 86% (18/21) of the sample receiving a CT scan at 6 months. The effect of CRC surveillance tests is commonly clinically approached as a bundle of care, that is, recommending the combination of colonoscopy, CEA testing, and imaging [44]. At baseline, only 42% (12/28) of participants reported having received all 3 tests, with 29% (8/28) not having received any. Whereas, at the 6-month follow-up, 77% (16/21) had received all 3 surveillance tests, and all patients had received at least one. Both CEA testing and CT scans have been associated with increased rates of surgical treatment of recurrence, suggesting that increases in either type of surveillance testing may be associated with more salvage surgery with curative intent [45].

### Comparison With Prior Work

Existing frameworks provide some guidance about what behavioral mechanisms may explain these main effects. The Health Belief Model [46] posits that self-efficacy, perceived barriers, and perceived benefits (ie, belief about the effectiveness of surveillance in reducing risk) mediate changes in the health behavior of individuals. Further, other investigators have postulated that patient-centered portals, with many features in common with personal health records, will have a positive effect upon patient self-efficacy [47-49]. In addition, Lo et al [50] found screening knowledge, perceived barriers to care, and social norms to be significant mediators of sociodemographic differences in the uptake of CRC screening. The CRCS-PHR may act through similar mechanisms. Our patient-centered technology had design features intended to increase screening knowledge and the perceived benefit of surveillance, including both clinical reminders to the patients about the next surveillance test due and web-based educational materials to explain the nature and purpose of each test. Participants found the summary and schedules of their cancer treatment and follow-up appointments to be the most useful in the PHR, along with side effects of treatment and community resources [31,47].

Due to the conceptual and empiric importance of patient knowledge, perceived benefits and barriers, as well as self-efficacy to the uptake of CRC screening [51], we explored the effect of the CRCS-PHR upon these secondary outcomes. Many patients did not know the answer to individual knowledge questions (Table 3); the proportion varied by test, from 25% (7/28) to 75% (21/28) for physical exam to colonoscopy, respectively. These findings suggest that patient-centered technologies have the potential to increase patient knowledge but can be further tailored to tests about which patients have the least awareness (eg, colonoscopy or CT scans). Nonetheless, patient knowledge is commonly not associated with changes in patient screening behavior [52]; our observations that surveillance test use increased, whereas knowledge about the tests often did not, reinforced this weak association.

Overall, patients largely agreed about the benefits of CRC surveillance, with the proportion who reported individual tests (colonoscopy, CEA test, or CT scan) as beneficial ranging from 75% to 100% (find recurrence early); from 68% to 88% (decrease chance of dying from recurrence); and from 71% to 89% (help you not to worry). With patient beliefs, the only domain that significantly increased was the perceived benefits of CEA testing, as most were quite high at baseline. These relatively high proportions are similar to the perceived benefit of CRC screening tests among a general population not already diagnosed with cancer [43]. High perceived benefit limited the potential for improvement in these perceptions among the CRC survivors enrolled in our trial. Conversely, low perceived barriers to care at baseline likely limited the potential for improvement in these domains. Moreover, the potential barriers of cost and transportation are challenging to address [53-58], and our CRCS-PHR implementation needs to be accompanied by changes in the health care systems, and policy needs to be adequately addressed.

We found no significant differences in patient self-efficacy. Systematic reviews conducted by Han et al [47] and Lancaster et al [48] found that eHealth tools such as provider-patient communication functionalities, case management, and other forms of clinical support may increase self-efficacy and self-management. Empiric findings from previous studies have been mixed. Secure messaging had a positive impact upon medication self-efficacy among patients with diabetes [59,60], but

other studies have shown no association [60]. These mixed findings suggest that the influence of patient portals upon self-efficacy may vary depending upon both the functions used and the populations targeted.

Future studies in the field of cancer control should assess new populations of patients with cancer, including prostate, ovarian, and skin cancers, as they are underrepresented in this area of the literature and patient-centered technology [31]. However, with differences across sites of cancer, and more specifically, across the cancer continuum, patient-centered technology interventions will need to be targeted toward specific sites and continuum levels as efficacy and effectiveness may vary [31]. This may be due in part to the complexity of cancer care across the care trajectory versus other chronic disease management, as well as the need for tailored functionalities by cancer type. Treatment plans and surveillance testing will likely differ for each cancer type in terms of the tests and intervals recommended. Future studies should also consider what types of recruitment strategies may be optimal in this type of research, such as recruitment through clinicians versus registry-based outreach. We employed a recruitment strategy involving clinician engagement to recruit individuals, as we felt this approach would better identify eligible patients and decrease attrition over time due to ongoing engagement with their clinicians. Testing this type of engagement was important to assess initial intervention feasibility. However, there are advantages to registry-based recruitment, which is more likely to lead to increased access to a larger number of potential participants. Researchers should weigh the advantages and disadvantages of different recruitment strategies in relation to the specific needs of their studies.

## Limitations

While this work provides strong insights and evidence to inform the development of the CRCs-PHR, our work is not without its limitations. First, without a control group not exposed to the CRCs-PHR, we are limited in our ability to make inferences of the intervention effect. Additionally, the pre- and posttest design has the potential for a temporal effect on the patient beliefs and surveillance receipt over time, which is important to note. With feasibility established, future studies should use a randomized controlled trial design, which will account for the potential of a temporal effect and increase the strength of our causal inferences with the introduction of a control group. The relatively small sample size of our feasibility study also limits our ability to test mediation pathways. Our sample was primarily White, younger on average compared with the national CRC population (58 years versus 66 years old) [1], and more highly educated than the population of Indiana and that of the United States (13/28, 46% of the sample having college degree). The young age and higher education of our sample is not unusual among early adopters of new patient technologies and cancer survivors recruited at academic medical centers [60-62]; however, the results are not directly generalizable to other populations, including patients treated in community-based oncology clinics. Future work needs to continue to focus upon how best to engage CRC survivors who tend to be older adults in use of these new technologies. While our sample had a majority of rectal patients, nearly an inverse of the US CRC survivor population (70% of national CRC survivors being colon), we believe it is important to understand the use of this technology among both rectal and colon cancer survivors, and do not have a reason to believe its use would

differ between these closely related cancer types. The higher proportion of rectal to colon patients in the sample was due in part to the local expertise in rectal cancer surgery at one of the academic sites.

## Conclusions

Patient-centered technologies such as the CRCS-PHR represent an important potential approach to improving the receipt of guideline-concordant care such as surveillance tests among cancer survivors. In assessing these rapidly emerging technologies, we encourage investigators and evaluators to continue measuring behavioral constructs that might serve as plausible mechanisms to explain observed effects. With this approach, we can grow to understand not only if new technologies improve the quality of care but how this improvement takes place. Future research in this area should also assess the effect of personal health records with quasi-experimental and randomized controlled study designs when possible. Finally, survivors of different types of cancers should be enrolled in future research, given that the clinical and supportive care needs of patients may vary widely among different populations.

## Acknowledgments

---

Funding for this project was provided by the Livestrong Foundation and the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Project #CDA 07-016 (DAH). Funding was also provided by the National Institutes of Health/National Cancer Institute Training Grant T32CA117865 (EV).

The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

## Abbreviations

CEA	carcinoembryonic antigen
CRC	colorectal cancer
CRCS	colorectal cancer survivors
CRCS-PHR	Colorectal Cancer Survivor Personal Health Record
CT	computed tomography
GSE	General Self-Efficacy
PHR	personal health record
VA	Veterans Affairs

---

## Multimedia Appendix 1

General self-efficacy measure.

[Click here to view.](#)<sup>(14K, docx)</sup>

## Footnotes

---

Conflicts of Interest: None declared.

## References

---

1. American Cancer Society. [2022-07-27]. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf> .
2. NCCN guidelines for colorectal cancer screening. *National Comprehensive Cancer Network*. [2022-07-27]. <https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations/GetFileFromFileManager?fileManagerId=13733> .

3. Chiorean EG, Nandakumar G, Fadelu T, Temin S, Alarcon-Rozas AE, Bejarano S, Croitoru A, Grover S, Lohar PV, Odhiambo A, Park SH, Garcia ER, Teh C, Rose A, Zaki B, Chamberlin MD. Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. *JCO Global Oncology*. 2020 Nov;(6):414–438. doi: 10.1200/jgo.19.00367. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
4. Costas-Chavarri A, Nandakumar G, Temin S, Lopes G, Cervantes A, Cruz Correa M, Engineer R, Hamashima C, Ho GF, Huitzil FD, Malekzadeh Moghani M, Sharara AI, Stern MC, Teh C, Vázquez Manjarrez SE, Verjee A, Yantiss R, Shah MA. Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. *JGO*. 2019 Dec;(5):1–19. doi: 10.1200/jgo.18.00214. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
5. Paulson EC, Veenstra CM, Vachani A, Ciunci CA, Epstein AJ. Trends in surveillance for resected colorectal cancer, 2001–2009. *Cancer*. 2015 Oct 01;121(19):3525–33. doi: 10.1002/cncr.29469. doi: 10.1002/cncr.29469. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[CrossRef](#)] [[Google Scholar](#)]
6. Sehdev A, Sherer EA, Hui SL, Wu J, Haggstrom DA. Patterns of computed tomography surveillance in survivors of colorectal cancer at Veterans Health Administration facilities. *Cancer*. 2017 Jun 15;123(12):2338–2351. doi: 10.1002/cncr.30569. doi: 10.1002/cncr.30569. [[PubMed](#)] [[CrossRef](#)] [[CrossRef](#)] [[Google Scholar](#)]
7. van der Stok EP, Spaander MCW, Grünhagen DJ, Verhoef C, Kuipers EJ. Surveillance after curative treatment for colorectal cancer. *Nat Rev Clin Oncol*. 2017 May 20;14(5):297–315. doi: 10.1038/nrclinonc.2016.199.nrclinonc.2016.199 [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
8. Garwood V, Lisy K, Jefford M. Survivorship in Colorectal Cancer: A Cohort Study of the Patterns and Documented Content of Follow-Up Visits. *J Clin Med*. 2020 Aug 24;9(9):2725. doi: 10.3390/jcm9092725. <https://www.mdpi.com/resolver?pii=jcm9092725> .jcm9092725 [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
9. Kupfer SS, Lubner S, Coronel E, Pickhardt PJ, Tipping M, Graffy P, Keenan E, Ross E, Li T, Weinberg DS. Adherence to postresection colorectal cancer surveillance at National Cancer Institute-designated Comprehensive Cancer Centers. *Cancer Med*. 2018 Nov 18;7(11):5351–5358. doi: 10.1002/cam4.1678. doi: 10.1002/cam4.1678. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[CrossRef](#)] [[Google Scholar](#)]
10. McDougall J, Banegas M, Wiggins C, Chiu V, Rajput A, Kinney A. Rural Disparities in Treatment-Related Financial Hardship and Adherence to Surveillance Colonoscopy in Diverse Colorectal Cancer Survivors. *Cancer Epidemiol Biomarkers Prev*. 2018 Nov;27(11):1275–1282. doi: 10.1158/1055-9965.EPI-17-1083. <http://europepmc.org/abstract/MED/29593011> .1055-9965.EPI-17-1083 [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
11. Mollica MA, Enewold LR, Lines LM, Halpern MT, Schumacher JR, Hays RD, Gibson JT, Schussler N, Kent EE. Examining colorectal cancer survivors' surveillance patterns and experiences of care: a SEER-CAHPS study. *Cancer Causes Control*. 2017 Oct 2;28(10):1133–1141. doi: 10.1007/s10552-017-0947-2.10.1007/s10552-017-0947-2 [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
12. Dendere R, Slade C, Burton-Jones A, Sullivan C, Staib A, Janda M. Patient Portals Facilitating Engagement With Inpatient Electronic Medical Records: A Systematic Review. *J Med Internet Res*. 2019 Apr 11;21(4):e12779. doi: 10.2196/12779. <https://www.jmir.org/2019/4/e12779/> v21i4e12779 [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
13. Neves AL, Freise L, Laranjo L, Carter AW, Darzi A, Mayer E. Impact of providing patients access to electronic health records on quality and safety of care: a systematic review and meta-analysis. *BMJ Qual Saf*. 2020 Dec 12;29(12):1019–1032. doi: 10.1136/bmjqs-2019-010581. <http://qualitysafety.bmj.com/lookup/pmidlookup?view=long&pmid=32532814> .bmjqs-2019-010581 [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

14. Tapuria A, Porat T, Kalra D, Dsouza G, Xiaohui S, Curcin V. Impact of patient access to their electronic health record: systematic review. *Inform Health Soc Care*. 2021 Jun 02;46(2):192–204. doi: 10.1080/17538157.2021.1879810. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
15. Turner K, Hong Y, Yadav S, Huo J, Mainous A. Patient portal utilization: before and after stage 2 electronic health record meaningful use. *J Am Med Inform Assoc*. 2019 Oct 01;26(10):960–967. doi: 10.1093/jamia/ocz030. <http://europepmc.org/abstract/MED/30947331> .5427963 [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
16. Dyer KE, Shires DA, Flocke SA, Hawley ST, Jones RM, Resnicow K, Shin Y, Lafata JE. Patient-Reported Needs Following a Referral for Colorectal Cancer Screening. *Am J Prev Med*. 2019 Feb;56(2):271–280. doi: 10.1016/j.amepre.2018.08.017. <http://europepmc.org/abstract/MED/30554975> .S0749-3797(18)32225-6 [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
17. Paydar S, Emami H, Asadi F, Moghaddasi H, Hosseini A. Functions and Outcomes of Personal Health Records for Patients with Chronic Diseases: A Systematic Review. *Perspect Health Inf Manag*. 2021;18(Spring):11.phim0018-0001m [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
18. Fatoum H, Hanna S, Halamka JD, Sicker DC, Spangenberg P, Hashmi SK. Blockchain Integration With Digital Technology and the Future of Health Care Ecosystems: Systematic Review. *J Med Internet Res*. 2021 Nov 02;23(11):e19846. doi: 10.2196/19846. <https://www.jmir.org/2021/11/e19846/> v23i11e19846 [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
19. Gandrup J, Ali S, McBeth J, van der Veer SN, Dixon W. Remote symptom monitoring integrated into electronic health records: A systematic review. *J Am Med Inform Assoc*. 2020 Nov 01;27(11):1752–1763. doi: 10.1093/jamia/ocaa177. <http://europepmc.org/abstract/MED/32968785> .5910715 [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
20. Luoh RP, Tevaarwerk AJ, Chandereeng T, Smith EM, Carroll CB, Emamekhoo H, Sesto ME. Patterns and predictors of cancer-specific patient health portal usage among patients with cancer: results from the UWCCC Survivorship Program. *Cancer Med*. 2021 Oct 28;10(20):7373–7382. doi: 10.1002/cam4.4234. doi: 10.1002/cam4.4234. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[CrossRef](#)] [[Google Scholar](#)]
21. Rodriguez ES. Using Patient Portals to Increase Engagement in Patients with Cancer. *Semin Oncol Nurs*. 2018 May;34(2):177–183. doi: 10.1016/j.soncn.2018.03.009.S0749-2081(18)30022-6 [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
22. Cancer-related information seeking among cancer survivors. *Health Information National Trends Survey*. 2015. [2022-07-27]. [https://hints.cancer.gov/docs/Briefs/HINTS\\_Brief\\_30.pdf](https://hints.cancer.gov/docs/Briefs/HINTS_Brief_30.pdf) .
23. Growth in Patient-Provider Internet Communication (2003-2013) *Health Information National Trends Survey*. 2019. [2022-07-27]. [https://hints.cancer.gov/docs/Briefs/HINTS\\_Brief\\_38.pdf](https://hints.cancer.gov/docs/Briefs/HINTS_Brief_38.pdf) .
24. Digital health tools to support cancer survivorship. *Health Information National Trends Survey*. 2021. [2022-07-27]. [https://hints.cancer.gov/docs/Briefs/HINTS\\_Brief\\_46.pdf](https://hints.cancer.gov/docs/Briefs/HINTS_Brief_46.pdf) .
25. Trends and disparities in patient portal use. *Health Information National Trends Survey*. [2022-07-27]. [https://hints.cancer.gov/docs/Briefs/HINTS\\_Brief\\_45.pdf](https://hints.cancer.gov/docs/Briefs/HINTS_Brief_45.pdf) .
26. Callan JA, Irizarry T, Nilsen ML, Mecca LP, Shoemaker J, Dabbs AD. Engagement in Health Care From the Perspective of Older Adults. *Res Gerontol Nurs*. 2021 May;14(3):138–149. doi: 10.3928/19404921-20210324-01. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

27. Joseph L, Lavis A, Greenfield S, Boban D, Humphries C, Jose P, Jeemon P, Manaseki-Holland S. Systematic review on the use of patient-held health records in low-income and middle-income countries. *BMJ Open*. 2021 Sep 02;11(9):e046965. doi: 10.1136/bmjopen-2020-046965. <https://bmjopen.bmj.com/lookup/pmidlookup?view=long&pmid=34475153>. [\[PMC free article\]](#) [\[PubMed\]](#) [\[CrossRef\]](#) [\[Google Scholar\]](#)
28. Kim S, Fadem S. Communication matters: Exploring older adults' current use of patient portals. *Int J Med Inform*. 2018 Dec;120:126–136. doi: 10.1016/j.ijmedinf.2018.10.004.S1386-5056(18)30280-6 [\[PubMed\]](#) [\[CrossRef\]](#) [\[Google Scholar\]](#)
29. Turner AM, Osterhage K, Hartzler A, Joe J, Lin L, Kanagat N, Demiris G. Use of Patient Portals for Personal Health Information Management: The Older Adult Perspective. *AMIA Annu Symp Proc*. 2015;2015:1234–41. <http://europepmc.org/abstract/MED/26958263>. [\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#)
30. Coughlin S, Caplan L, Young L. A Review of Web Portal Use by Oncology Patients. *J Cancer Treatment Diagn*. 2018 Nov 1;2(6):1–6. doi: 10.29245/2578-2967/2018/6.1154. <http://europepmc.org/abstract/MED/30680374>. [\[PMC free article\]](#) [\[PubMed\]](#) [\[CrossRef\]](#) [\[Google Scholar\]](#)
31. Tarver W, Menachemi N. The impact of health information technology on cancer care across the continuum: a systematic review and meta-analysis. *J Am Med Inform Assoc*. 2016 Mar;23(2):420–7. doi: 10.1093/jamia/ocv064. <http://europepmc.org/abstract/MED/26177658>. [\[PMC free article\]](#) [\[PubMed\]](#) [\[CrossRef\]](#) [\[Google Scholar\]](#)
32. Kushniruk AW, Patel VL. Cognitive and usability engineering methods for the evaluation of clinical information systems. *J Biomed Inform*. 2004 Feb;37(1):56–76. doi: 10.1016/j.jbi.2004.01.003. <https://linkinghub.elsevier.com/retrieve/pii/S1532046404000206>. [\[PubMed\]](#) [\[CrossRef\]](#) [\[Google Scholar\]](#)
33. Haggstrom DA, Carr T. Uses of Personal Health Records for Communication Among Colorectal Cancer Survivors, Caregivers, and Providers: Interview and Observational Study in a Human-Computer Interaction Laboratory. *JMIR Hum Factors*. 2022 Jan 25;9(1):e16447. doi: 10.2196/16447. <https://humanfactors.jmir.org/2022/1/e16447/> v9i1e16447 [\[PMC free article\]](#) [\[PubMed\]](#) [\[CrossRef\]](#) [\[Google Scholar\]](#)
34. Nielsen J. *Usability Engineering*. Boston, USA: Academic Press; 1993. [\[Google Scholar\]](#)
35. Rawl SM, Champion VL, Scott LL, Zhou H, Monahan P, Ding Y, Loehrer P, Skinner CS. A randomized trial of two print interventions to increase colon cancer screening among first-degree relatives. *Patient Educ Couns*. 2008 May;71(2):215–27. doi: 10.1016/j.pec.2008.01.013. <http://europepmc.org/abstract/MED/18308500>. [\[PubMed\]](#) [\[CrossRef\]](#) [\[Google Scholar\]](#)
36. Walther JB, Pingree S, Hawkins RP, Buller DB. Attributes of interactive online health information systems. *J Med Internet Res*. 2005 Jul 01;7(3):e33. doi: 10.2196/jmir.7.3.e33. <https://www.jmir.org/2005/3/e33/> v7i3e33 [\[PMC free article\]](#) [\[PubMed\]](#) [\[CrossRef\]](#) [\[Google Scholar\]](#)
37. Bhandari A, Wagner T. Self-reported utilization of health care services: improving measurement and accuracy. *Med Care Res Rev*. 2006 Apr 18;63(2):217–35. doi: 10.1177/1077558705285298.63/2/217 [\[PubMed\]](#) [\[CrossRef\]](#) [\[Google Scholar\]](#)
38. Short M, Goetzel R, Pei X, Tabrizi M, Ozminkowski R, Gibson T, Dejoy DM, Wilson MG. How accurate are self-reports? Analysis of self-reported health care utilization and absence when compared with administrative data. *J Occup Environ Med*. 2009 Jul;51(7):786–96. doi: 10.1097/JOM.0b013e3181a86671. <http://europepmc.org/abstract/MED/19528832>. [\[PMC free article\]](#) [\[PubMed\]](#) [\[CrossRef\]](#) [\[Google Scholar\]](#)
39. Smyth J, Webb M, Oikawa M. Self-report of cancer-related behaviors. *National Cancer Institute*. 2020. [2022-07-27]. <https://cancercontrol.cancer.gov/sites/default/files/2020-06/self-report.pdf>.

40. United States Department of Health and Human Services. National Center for Health Statistics National Health Interview Survey. *National Institute on Aging*. 2006 Jan 18;:1–242. doi: 10.3886/ICPSR02533.v1. [[CrossRef](#)] [[Google Scholar](#)]

41. Luszczynska A, Scholz U, Schwarzer R. The General Self-Efficacy Scale: Multicultural Validation Studies. *The Journal of Psychology*. 2005 Sep;139(5):439–457. doi: 10.3200/jrlp.139.5.439-457. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

42. Rawl SM, Menon U, Champion VL, Foster JL, Skinner CS. Colorectal cancer screening beliefs. Focus groups with first-degree relatives. *Cancer Pract*. 2000 Jan;8(1):32–7. doi: 10.1046/j.1523-5394.2000.81006.x. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

43. Rawl SM, Menon U, Champion VL, May FE, Loehrer P, Hunter C, Azzouz F, Monahan PO, Skinner CS. Do benefits and barriers differ by stage of adoption for colorectal cancer screening? *Health Educ Res*. 2005 Apr 14;20(2):137–48. doi: 10.1093/her/cyg110.cyg110 [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

44. Jeffery M, Hickey B, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. *Cochrane Database Syst Rev*. 2002;9(1):CD002200. doi: 10.1002/14651858.CD002200.CD002200 [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

45. Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, George S, Mant D, FACS Trial Investigators Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. *JAMA*. 2014 Jan 15;311(3):263–70. doi: 10.1001/jama.2013.285718.1814213 [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

46. Rosenstock IM. Why People Use Health Services. *The Milbank Memorial Fund Quarterly*. 1966 Jul;44(3):94. doi: 10.2307/3348967. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

47. Han H, Gleason KT, Sun C, Miller HN, Kang SJ, Chow S, Anderson R, Nagy P, Bauer T. Using Patient Portals to Improve Patient Outcomes: Systematic Review. *JMIR Hum Factors*. 2019 Dec 19;6(4):e15038. doi: 10.2196/15038. <https://humanfactors.jmir.org/2019/4/e15038/> v6i4e15038 [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

48. Lancaster K, Abuzour A, Khaira M, Mathers A, Chan A, Bui V, Lok A, Thabane L, Dolovich L. The Use and Effects of Electronic Health Tools for Patient Self-Monitoring and Reporting of Outcomes Following Medication Use: Systematic Review. *J Med Internet Res*. 2018 Dec 18;20(12):e294. doi: 10.2196/jmir.9284. <https://www.jmir.org/2018/12/e294/v20i12e294> [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

49. Nahm E, Diblasi C, Gonzales E, Silver K, Zhu S, Sagherian K, Kongs K. Patient-Centered Personal Health Record and Portal Implementation Toolkit for Ambulatory Clinics: A Feasibility Study. *Comput Inform Nurs*. 2017 Apr;35(4):176–185. doi: 10.1097/CIN.0000000000000318. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

50. Lo SH, Waller J, Vrinten C, Kobayashi L, von Wagner C. Social Cognitive Mediators of Sociodemographic Differences in Colorectal Cancer Screening Uptake. *Biomed Res Int*. 2015;2015:165074–9. doi: 10.1155/2015/165074. doi: 10.1155/2015/165074. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[CrossRef](#)] [[Google Scholar](#)]

51. Kiviniemi MT, Bennett A, Zaiter M, Marshall JR. Individual-level factors in colorectal cancer screening: a review of the literature on the relation of individual-level health behavior constructs and screening behavior. *Psychooncology*. 2011 Oct 27;20(10):1023–33. doi: 10.1002/pon.1865. <http://europemc.org/abstract/MED/21954045> . [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

52. Eibich P, Goldzahl L. Health information provision, health knowledge and health behaviours: Evidence from breast cancer screening. *Soc Sci Med*. 2020 Nov;265:113505. doi: 10.1016/j.socscimed.2020.113505. [https://linkinghub.elsevier.com/retrieve/pii/S0277-9536\(20\)30724-3](https://linkinghub.elsevier.com/retrieve/pii/S0277-9536(20)30724-3) .S0277-9536(20)30724-3 [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

53. Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. *CA Cancer J Clin*. 2018 Mar 16;68(2):153–165. doi: 10.3322/caac.21443. doi: 10.3322/caac.21443. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[CrossRef](#)] [[Google Scholar](#)]
54. Lentz R, Benson AB, Kircher S. Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies. *J Surg Oncol*. 2019 Jul 16;120(1):85–92. doi: 10.1002/jso.25374. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
55. Mols F, Tomalin B, Pearce A, Kaambwa B, Koczwara B. Financial toxicity and employment status in cancer survivors. A systematic literature review. *Support Care Cancer*. 2020 Dec 31;28(12):5693–5708. doi: 10.1007/s00520-020-05719-z. <http://europepmc.org/abstract/MED/32865673> .10.1007/s00520-020-05719-z [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
56. Smith G, Lopez-Olivo M, Advani P, Ning M, Geng Y, Giordano S, Volk RJ. Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes. *J Natl Compr Canc Netw*. 2019 Oct 01;17(10):1184–1192. doi: 10.6004/jnccn.2019.7305. <http://europepmc.org/abstract/MED/31590147> .jnccn18181 [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
57. Zafar S, Abernethy A. Financial toxicity, Part II: how can we help with the burden of treatment-related costs? *Oncology (Williston Park)* 2013 Apr;27(4):253–254. <http://www.cancernetwork.com/practice-policy/financial-toxicity-part-ii-how-can-we-help-burden-treatment-related-costs> .168926 [[PubMed](#)] [[Google Scholar](#)]
58. Zafar SY, Newcomer LN, McCarthy J, Fuld Nasso S, Saltz LB. How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives. *American Society of Clinical Oncology Educational Book*. 2017 May;(37):35–39. doi: 10.1200/edbk\_174893. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
59. de Jong CC, Ros WJ, van Leeuwen M, Schrijvers G. Exploring the effects of patients taking a vigilant role in collaborating on their e-medication administration record. *Int J Med Inform*. 2016 Apr;88:18–24. doi: 10.1016/j.ijmedinf.2016.01.001.S1386-5056(16)30001-6 [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
60. Ancker JS, Osorio SN, Cheriff A, Cole CL, Silver M, Kaushal R. Patient activation and use of an electronic patient portal. *Inform Health Soc Care*. 2015 Apr 30;40(3):254–66. doi: 10.3109/17538157.2014.908200. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
61. Cheung WY, Aziz N, Noone A, Rowland JH, Potosky AL, Ayanian JZ, Virgo KS, Ganz PA, Stefanek M, Earle CC. Physician preferences and attitudes regarding different models of cancer survivorship care: a comparison of primary care providers and oncologists. *J Cancer Surviv*. 2013 Sep 24;7(3):343–54. doi: 10.1007/s11764-013-0281-y. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
62. Cheung WY, Neville BA, Earle CC. Associations Among Cancer Survivorship Discussions, Patient and Physician Expectations, and Receipt of Follow-Up Care. *JCO*. 2010 May 20;28(15):2577–2583. doi: 10.1200/jco.2009.26.4549. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]